People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

Researchers Identify a Potential Biomarker of Parkinson's Disease Progression Nov. 12 ... are detected in blood once symptoms have started in Lewy's body diseases, ... July 8, 2024 — By ...

Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

She was happily married, pregnant with her first child and had recently completed her residency in family medicine. Soon ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...